LY2606368
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for LY2606368, covering 2022-02-09 to 2022-09-10. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer [Phase 2]